Crystal Wong, MD

Study examines relationship between cardiovascular disease risk factors, rotator cuff tendinopathy, and glenohumeral joint pain.

Researchers look for diagnostic alternative to blood samples for diagnosing specific inflammatory arthritis conditions.

Intra-articular corticosteroid injections for knee osteoarthritis may improve pain and physical function for up to 6 weeks.

New analysis compares the risk of serious adverse events among all 10 FDA-approved biological and targeted synthetic disease-modifying antirheumatic drugs.

Post hoc study subgroup analysis shows combination ambrisentan plus tadalafil therapy improves treatment response in patients with connective tissue disease-associated pulmonary arterial hypertension.

Pooled results examine the incidence of antidrug antibody development after both intravenous and subcutaneously administered tocilizumab for rheumatoid arthritis.

New research compared treatment efficacy by drug class and clinical and humanistic burdens of nr-axSpA with those of AS.

A phase 3 trial examined the superiority of sarilumab monotherapy compared with adalimumab monotherapy in patients who were either intolerant of or inappropriate candidates for methotrexate therapy.

“Exercise-based motivational interviewing was associated with sustained clinical benefits 6 months after completion of therapy, but only for those who were not taking opioids.”

An international EULAR taskforce has derived a set of clinical parameters to aid in identifying patients who may have CSA.

Study examines the relationship between bone marrow edema and neck pain in patients with rheumatoid arthritis and ankylosing spondylitis.

The reproducibility of radiographic SIJ classification and potential drivers of disagreement were examined in a SpA inception cohort.

A recent investigation found that very low sodium intake may actually increase the risk for CVD and mortality.

Targeted IL-6 inhibition with sirukumab did not demonstrate efficacy or acceptable safety in patients with active lupus nephritis concomitantly receiving immunosupprsant therapy.

The current study evaluated the relationship between serum C3 levels and whole-body insulin sensitivity in nondiabetic patients with PsA.

Tumor necrosis factor promoter polymorphisms were stronger predictors of response to etanercept than to infliximab or adalimumab in patients with spondyloarthritis.

Researchers compared the pharmacokinetics, safety, and efficacy of CT-P10, a rituximab candidate biosimilar, with innovator rituximab in patients with RA refractory to TNF inhibitors.

Although individual patients’ metablome profiles may vary with disease activity, metabolic profiling can identify variations between responders and non-responders to TNF.

Patients randomized to discontinuing TNFis were at increased risk of experiencing a disease flare within 12 months.

Incentive payments that encourage primary care physicians (PCPs) to provide comprehensive preventive patient care did not result in reduced hospitalizations or cost.

Rituximab was as effective as TNF inhibitors but was less costly in rheumatoid arthritis patients who were refractory to non-biologic DMARDs.